Maintenance Notice (3:15 - 7:30 AM February 22, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Notice of Discontinuing the Use of Password-Protected Compressed Files | Product Document Searching Made Easy by 2D Code! | TCI Life Science News February 2025 | [Product Highlights] Chemiluminescent Reagents for... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 29094-61-9 | 产品编码: G0369
Glipizide
×
![]()
×
| 产品编码 | G0369 |
| 纯度/分析方法 | >98.0%(T)(HPLC) |
| 分子式/分子量 | C__2__1H__2__7N__5O__4S = 445.54 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 室温 (15°C以下阴凉干燥处) |
| 包装和容器 | 1G-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 29094-61-9 |
| Reaxys-RN | 903495 |
| PubChem物质ID | 125307849 |
| SDBS (AIST Spectral DB) | 52971 |
| Merck Index (14) | 4442 |
| MDL编号 | MFCD00072159 |
技术规格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
物性（参考值）
| 熔点 | 206 °C |
GHS
相关法规
| RTECS# | YS7640000 |
运输信息
| HS编码* | 2935.90-000 |
应用
Glipizide: A Sulfonylurea ATP-Dependent K+ Channel Antagonist
Glipizide belongs to sulfonylurea antidiabetics which increase the release of insulin from pancreatic B-cells. Sulfonylurea antidiabetics inhibit ATP-gated K+ channels and thereby cause depolarization of the B-cell membrane. The depolarization leads to activation of voltage-dependent Ca channels and Ca2+ influx into the B-cell, and eventually increases insulin release. In addition, glipizide is characterized by poor solubility in water. Therefore, it has been studied to improve the solubility and bioavailability of drug. (The product is for research purpose only. (The product is for research purpose only.)
References
- Glipizide: a review of its pharmacological properties and therapeutic use
- The receptor for antidiabetic sulfonylureas controls the activity of the ATP-modulated K+ channel in insulin-secreting cells
- Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening
- Enhancement of the dissolution rate and bioavailability of glipizide through cyclodextrin inclusion complex
- Development of a controlled release low dose class II drug-Glipizide
- The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide, or glimperide in plasma
- Simultaneous estimation of six anti-diabetic drugs-glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay
参考文献
文章/手册
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。